Cannabis use disorder is one of the most under-recognized and under-treated substance use conditions. The cultural normalization of marijuana — accelerated by legalization trends — has created a widespread belief that cannabis "isn't addictive." The clinical reality is different: the DSM-5 recognizes cannabis use disorder as a diagnosable condition, and an estimated 10% of regular users develop problematic patterns that meet diagnostic criteria. For these individuals, the dismissal of their struggle by friends, family, and sometimes even healthcare providers prevents them from seeking the help they need.
Cannabis use disorder is real, diagnosable, and treatable. There is no FDA-approved medication specifically for cannabis addiction, so treatment relies on behavioral therapies — CBT, motivational enhancement therapy, and contingency management — delivered with enough intensity and duration to create lasting change. Colombian residential programs provide this intensity at accessible pricing.
DSM-5 Diagnostic Criteria
Cannabis use disorder is diagnosed when cannabis use leads to clinically significant impairment or distress, manifested by at least two of the following within a 12-month period: using more than intended, inability to cut down despite wanting to, spending excessive time obtaining or using cannabis, cravings, failing to fulfill major obligations, continued use despite social problems, giving up activities for cannabis use, use in hazardous situations, continued use despite physical or psychological problems, tolerance, and withdrawal. Mild = 2-3 symptoms; moderate = 4-5; severe = 6+.
Treatment Approaches
CBT: Identifies triggers and develops alternative coping strategies. The most studied intervention for cannabis use disorder, with moderate evidence of effectiveness.
Motivational Enhancement Therapy (MET): Addresses the ambivalence that characterizes many cannabis users seeking treatment ("I know it's a problem, but is it really bad enough to stop?"). MET resolves this ambivalence and strengthens commitment to change.
Contingency Management: Provides tangible reinforcement for verified abstinence, particularly effective in the early treatment phase.
Emerging Research (NAC): N-acetylcysteine (NAC) has shown promise in clinical trials for reducing cannabis use, particularly in adolescents and young adults. It is not FDA-approved for this indication but is available as a supplement and is being studied further.
Why Residential Treatment for Cannabis?
Many people question whether residential treatment is necessary for cannabis — after all, it is not physically dangerous like alcohol or opioid withdrawal. But for individuals with severe cannabis use disorder, the pattern is deeply embedded in daily routines, social environments, and emotional coping. Outpatient treatment can work for mild cases, but severe cannabis use disorder — where the person has been using daily for years and has organized their entire lifestyle around cannabis — often requires the environmental change and therapeutic intensity that residential treatment provides.
People struggling with cannabis use disorder face a unique form of invalidation: others tell them their problem is not real, that they should just stop, or that cannabis is not "addictive enough" to warrant treatment. This dismissal is itself a barrier to recovery. If cannabis is interfering with your life, your relationships, your motivation, or your wellbeing — and you have been unable to change your pattern on your own — your experience is valid, your struggle is real, and treatment is available.
Start Your Recovery Journey
Confidential consultation with experienced treatment professionals. No pressure, no judgment — just honest guidance about your options.
Chat Confidentially on WhatsApp